<DOC>
	<DOC>NCT01588236</DOC>
	<brief_summary>The purpose of this study is to further assess the efficacy, safety and dose-response of KYG0395 in the treatment of primary dysmenorrhea.</brief_summary>
	<brief_title>Effect of KYG0395 on Primary Dysmenorrhea</brief_title>
	<detailed_description />
	<mesh_term>Dysmenorrhea</mesh_term>
	<criteria>Otherwise healthy female subjects (age between 18 and 35, BMI equals or less than 32),with primary dysmenorrhea for at least 3 consecutive menstrual cycles prior to the study (prior to the start of the baseline cycles) and with VAS score &gt; 70 for the maximum dysmenorrheic pain or VAS score &gt; 40 for the average daily dysmenorrheic pain of the last menstrual cycle. Known or suspected to have secondary dysmenorrhea due to pelvic inflammation, endometriosis, uterine myomata, ovarian pathological changes, or other pelvic diseases. Pregnant or trying to conceive during the study. Recent delivery, abortion, or lactation within 3 menstrual cycles before the start of treatment.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>